Is Monosomy of Chromosome 9 Linked to Adverse Outcomes in Renal Cell Carcinoma?
RTK Inhibitor Plus Immunotherapy in Advanced Kidney Cancer
FDA Accepts Biologics License Application for Proposed Biosimilar To Bevacizumab
GU Cancers Symposium 2020: Novel Agent May Inhibit Oncogenic Driver in Kidney Cancer
Metastatic Abscesses During Pazopanib Treatment: An Underdescribed Risk?
Perioperative Change in Renal Function: Prognostic Indicator in Renal Cell Carcinoma?
HIF-2α Protein and Progression of Clear Cell Kidney Cancer
Adult Renal Cell Carcinoma Risk and Childhood Body Mass Index
Active Surveillance Safe for Small Renal Tumors
PD-1 Inhibitor Disappoints in mRCC With Untreated Brain Metastases
NCCN Guidelines® Insights – Kidney Cancer, Version 2.2020
NCCN Pharmacy Updates: Advances in Targeted Therapy and Immunotherapy for the Treatment of Kidney Cancer
University of Michigan Comprehensive Cancer Center
City of Hope Comprehensive Cancer Center
Vanderbilt-Ingram Cancer Center
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Lenvatinib Plus Everolimus (Renal Cell Carcinoma)
Cabozantinib (Renal Cell Carcinoma)
Nivolumab + Ipilimumab (Renal Cell Carcinoma)
Cancer.gov: What You Need To Know About Kidney Cancer
American Society of Clinical Oncology: Kidney Cancer
American Cancer Society: Kidney Cancer